Single vs. combination immunotherapeutic strategies for glioma

Expert Opinion on Biological Therapy

Volumn 17, Issue 5, 2017, Pages 543-554

  Chandran, Mayuri ^a   Candolfi, Marianela ^b   Shah, Diana ^a   Mineharu, Yohei ^c   Yadav, Viveka Nand ^a   Koschmann, Carl ^a   Asad, Antonela S ^b   Lowenstein, Pedro R ^a   Castro, Maria G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cancer vaccines; gene therapy; Glioma; immune checkpoint blockade; immunotherapy

Indexed keywords

DENDRITIC CELL VACCINE; PEPTIDE; PEPTIDE VACCINE; RINDOPEPIMUT; CANCER VACCINE; DACARBAZINE; TEMOZOLOMIDE;

BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; COMPARATIVE EFFECTIVENESS; GLIOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR MICROENVIRONMENT; VACCINATION; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; COMPARATIVE STUDY; GENE THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PROCEDURES;

ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; DACARBAZINE; GENETIC THERAPY; GLIOMA; HUMANS; IMMUNOTHERAPY;

EID: 85018261590     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2017.1305353     Document Type: Review

References (112)

1. Network TCGAR. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. New England J Med. 2015;372(26):2481–2498.
2. Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults:a “state of the science” review. Neuro Oncol. 2014;16(7):896–913.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England J Med. 2005;352(10):987–996.
4. Lowenstein PR, Kroeger K, Castro MG., Immunology of neurological gene therapy:how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses. Neurotherapeutics:J Am Soc Exp Neurotherapeutics. 2007;4(4):715–724.
5. Barcia C, Jimenez-Dalmaroni M, Kroeger KM, et al. One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity:clinical implications. Mol Ther. 2007;15(12):2154–2163.
6. Barcia C, Thomas CE, Curtin JF, et al. In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. J Exp Med. 2006;203(9):2095–2107.
7. Lowenstein PR, Castro MG., Recent advances in the pharmacology of neurological gene therapy. Curr Opin Pharmacol. 2004;4(1):91–97.
8. Galea I, Bernardes-Silva M, Forse PA, et al. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J Exp Med. 2007;204(9):2023–2030.
9. Klein RS, Garber C, Howard N. Infectious immunity in the central nervous system and brain function. Nat Immunol. 2017;18(2):132–141.
10. Savarin C, Bergmann Cornelia C, Hinton David R, et al. MMP-independent role of TIMP-1 at the blood brain barrier during viral encephalomyelitis. ASN Neuro. 2013;5(5):e00127.
11. Davies DC. Blood–brain barrier breakdown in septic encephalopathy and brain tumours. J Anat. 2002;200(6):639–646.
12. D’Agostino PM, Gottfried-Blackmore A, Anandasabapathy N, et al. Brain dendritic cells:biology and pathology. Acta Neuropathol. 2012;124(5):599–614.
13. Louveau A, Harris TH, Kipnis J. Revisiting the mechanisms of CNS immune privilege. Trends Immunol. 2015;36(10):569–577.
14. Perng P, Lim M. Immunosuppressive mechanisms of malignant gliomas:parallels at non-CNS sites. Front Oncol. 2015;5:153.
15. Nduom EK, Weller M, Heimberger AB. Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 2015;17(suppl7):vii9–vii14.
16. Appin CL, Brat DJ. Biomarker-driven diagnosis of diffuse gliomas. Mol Aspects Med. 2015;45:87–96.
17. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system:a summary. Acta Neuropathol. 2016;131(6):803–820.
18. Lai AA. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29(34):4482–4490.• Provides evidence that IDH1-mutant GBM arises from a unique cell type of origin and represents a different disease entity than IDH1–wild-type GBM.
19. Paugh B. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28(18):3061–3068.
20. Sturm D, Bender S, Jones DTW, et al. Paediatric and adult glioblastoma:multiform (epi)genomic culprits emerge. Nat Rev Cancer. 2014;14(2):92–107.
21. Fontebasso AM, Liu X-Y, Sturm D, et al. Chromatin remodeling defects in pediatric and young adult glioblastoma:a tale of a variant histone 3 tail. Brain Pathol. 2013;23(2):210–216.
22. Siegal T. Clinical relevance of prognostic and predictive molecular markers in gliomas. In:Schramm J, ed. Advances and technical standards in neurosurgery:volume 43. Cham:Springer International Publishing; 2016. p. 91–108.
23. Koschmann CC. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci Transl Med. 2016;8(328):328ra28–28ra28.• Shows that ATRX deficiency in a mouse model of GBM results in genetic instability and increased responsiveness to double-stranded DNA-damaging agents.
24. Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110.
25. Sottoriva A, Spiteri I, Piccirillo SGM, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013;110(10):4009–4014.
26. Pellegatta S, Cuppini L, Finocchiaro G. Brain cancer immunoediting:novel examples provided by immunotherapy of malignant gliomas. Expert Rev Anticancer Ther. 2011;11:1759–1774.
27. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722–4729.• Demonstrates that administration of an EGFRvIII-specific peptide vaccine results in an antigen-specific immune response and significant reduction in EGFRvIII expression upon tumor recurrence.
28. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001;23(2):263–272.
29. Qiu B, Zhang D, Wang C, et al. IL-10 and TGF-β2 are overexpressed in tumor spheres cultured from human gliomas. Mol Biol Rep. 2011;38(5):3585–3591.
30. Wainwright DADA. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clinical Cancer Research. 2012;18(22):6110–6121.
31. Fecci PE. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (Chicago, Ill). 2006;66(6):3294–3302.
32. Wu A, Wei J, Kong L-Y, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010;12(11):1113–1125.
33. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174.
34. Mirghorbani MM. Myeloid-derived suppressor cells in glioma. Expert Rev Neurother. 2013;13(12):1395–1406.
35. Didenko VV, Ngo HN, Minchew C, et al. Apoptosis of T lymphocytes invading glioblastomas multiforme:a possible tumor defense mechanism. J Neurosurg. 2002;96(3):580–584.
36. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells:a potential mechanism of immune paralysis. Cancer ResMech Immune Para. 2003;63(21):7462–7467.• Shows that B7-H1, strongly expressed on glioma cells but not found in normal brain tissues, is a strong inhibitor of CD4+ and CD8+ T cells.
37. Brunet J-F, Denizot F, Luciani M-F, et al. A new member of the immunoglobulin superfamily–CTLA-4. Nature. 1987;328(6127):267–270.
38. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25+ CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte–associated antigen 4. J Exp Med. 2000;192(2):303.
39. Egen JG, Kuhns MS, Allison JP. CTLA-4:new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3(7):611–618.• Summarizes the role of CTLA4 in the regulation of T-cell response and presents the CTLA4/TCR axis as a target for cancer immunotherapy.
40. Schwartz RHR. Costimulation of T lymphocytes:the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell (Cambridge). 1992;71(7):1065–1068.
41. Linsley PSP. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (Cambridge, Mass). 1994;1(9):793–801.•• Reports that CD80 and CD86 show similar overall T cell receptor binding and costimulatory properties, but CD80 binds CTLA4 with greater strength than CD86 and dissociates from CTLA4 more slowly than CD86.
42. Calinescu AA, Kamran N, Baker G, et al. Overview of current immunotherapeutic strategies for glioma. Immunotherapy. 2015;7(10):1073–1104.
43. Reardon DA, Freeman G, Wu C, et al. Immunotherapy advances for glioblastoma. Neuro Oncol. 2014;16(11):1441–1458.
44. Binder DC. Immunotherapy for cancer in the central nervous system:current and future directions. Oncoimmunology. 2016;5(2):e1082027.
45. Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev. 2008;222(1):70–100.
46. Kamran N, Calinescu A, Candolfi M, et al. Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther. 2016;16(10):1245–1264.
47. Hatanpaa KJ, Burma S, Zhao D, et al. Epidermal growth factor receptor in glioma:signal transduction, neuropathology, imaging, and radioresistance. Neoplasia (New York, NY). 2010;12(9):675–684.
48. Schuster J, Lai RK, Recht LD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma:the ACT III study. Neuro Oncol. 2015;17(6):854–861.
49. CelldexTherapeutics. Data safety and monitoring board recommends Celldex’s phase 3 study of RINTEGA® (rindopepimut) in newly diagnosed glioblastoma be discontinued as it is unlikely to meet primary overall survival endpoint in patients with minimal residual disease. Press Release. 2016. Available from:http://ir.celldex.com/releasedetail.cfm?ReleaseID=959021
50. Mineharu Y, Castro MG, Lowenstein PR, et al. Dendritic cell-based immunotherapy for glioma:multiple regimens and implications in clinical trials. Neurol Med Chir (Tokyo). 2013;53(11):741–754.
51. Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603–1615.
52. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol:Official J Am Soc Clin Oncol. 2011;29(3):330–336.• Demonstrates the ability of a DC vaccine loaded with glioma-associated antigen epitopes to induce antigen-specific immune responses, and improve 12-month progression-free status in patients with malignant glioma.
53. Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother:CII. 2013;62(1):125–135.
54. Hdeib A, Sloan AE. Dendritic cell immunotherapy for solid tumors:evaluation of the DCVax(R) platform in the treatment of glioblastoma multiforme. CNS Oncol. 2015;4(2):63–69.
55. Wainwright D. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20(20):5290–5301.
56. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. New England J Med. 2013;369(2):122–133.
57. Agarwalla P, Barnard Z, Fecci P, et al. Sequential immunotherapy by vaccination with GM-CSF expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immuno Ther (Hagerstown, Md:1997). 2012;35(5):385–389.
58. Duraiswamy JJ. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res (Chicago, Ill). 2013;73(12):3591–3603.• Demonstrates that blockade of both PD-1 and CTLA-4 resulted in proliferation of antigen-specific CD8+ T cells, reversing CD8+ T cell dysfunction.
59. Williams ELEL. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res. 2013;19(13):3545–3555.
60. Weber JSJS. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311–4318.
61. Maus MV. Designing CAR T cells for glioblastoma. Oncoimmunology. 2015;4(12):e1048956.
62. Sengupta S, Mao G, Gokaslan ZS, et al. Chimeric antigen receptors for treatment of glioblastoma:a practical review of challenges and ways to overcome them. Cancer Gene Ther. 2016;00:1–9.
63. Kakarla S, Gottschalk S. CAR T cells for solid tumors:armed and ready to go? Cancer J (Sudbury, Mass). 2014;20(2):151–155.
64. Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–3144.
65. Kosaka A, Ohkuri T, Okada H. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immuno Immunother. 2014;63(8):847–857.
66. Moertel CL, Xia J, LaRue R, et al. CD200 in CNS tumor-induced immunosuppression:the role for CD200 pathway blockade in targeted immunotherapy. J Immunother Cancer. 2014;2(1):46.
67. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer:harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269–281.
68. Madany M, Thomas TM, Edwards L, et al. Immunobiology and immunotherapeutic targeting of glioma stem cells. Adv Exp Med Biol. 2015;853:139–166.
69. Lin R, Sampson JH, Li Q-J, et al. miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment. Oncoimmunology. 2015;4(3):e990803.
70. Lin R, Chen L, Chen G, et al. Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J Clin Investig. 2014;124:5352–5367.
71. Curtin JF, Liu N, Candolfi M, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009;6(1):e10.•• Describes a novel mechanism of anti-GBM immune stimulation through HMGB1 release from dying tumor cells, resulting in TLR2 signaling.
72. Candolfi M, Kroeger KM, Muhammad AK, et al. Gene therapy for brain cancer:combination therapies provide enhanced efficacy and safety. Curr Gene Ther. 2009;9(5):409–421.
73. Okada H, Giezeman-Smits KM, Tahara H, et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther. 1999;6(2):219–226.
74. Okada H, Lieberman FS, Walter KA, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007;5:67.
75. Patel DM, Foreman PM, Nabors LB, et al. Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. Hum Gene Ther Clin Dev. 2016;27(2):69–78.
76. Mineharu Y, King GD, Muhammad AK, et al. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination:implications for clinical trial design. Clin Cancer Res. 2011;17(14):4705–4718.•• Reveals that immunostimulatory gene therapy with Ad-Flt3L/Ad-TK potentiates DC vaccination, resulting in a significant increase in survival when compared to each therapy alone.
77. Kamran N, Kadiyala P, Saxena M, et al. Immunosuppressive myeloid cells’ blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy. Mol Ther. 2016. DOI:10.1016/j.ymthe.2016.10.003.
78. Rampling R, Peoples S, Mulholland PJ, et al. A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin Cancer Res. 2016;22(19):4776.
79. Narusawa M, Inoue H, Sakamoto C, et al. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells. Cancer Immuno Res. 2014;2(6):568–580.
80. Ohkuri T, Ghosh A, Kosaka A, et al. Protective role of STING against gliomagenesis:rational use of STING agonist in anti-glioma immunotherapy. Oncoimmunology. 2015;4(4):e999523.
81. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009;460(7251):108–112.
82. Wang Y, Wang XY, Subjeck JR, et al. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer. 2011;104(4):643–652.
83. Mineharu Y, Kamran N, Lowenstein PR, et al. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Mol Cancer Ther. 2014;13(12):3024–3036.
84. Chaoul N, Fayolle C, Desrues B, et al. Rapamycin impairs antitumor CD8+ T-cell responses and vaccine-induced tumor eradication. Cancer Res. 2015;75(16):3279–3291.
85. Mitchell DA, Batich KA, Gunn MD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519(7543):366–369.
86. Pellegatta S, Valletta L, Corbetta C, et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun. 2015;3:4.
87. Karbach J, Gnjatic S, Bender A, et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51:association with survival. Int J Cancer. 2010;126(4):909–918.
88. Kostic A, Mihailovic D, Veselinovic S, et al. Tumor size and karyometric variables in brain astrocytoma. J BUON. 2009;14(3):473–477.
89. Markovic SN, Suman VJ, Ingle JN, et al. Peptide vaccination of patients with metastatic melanoma:improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol. 2006;29(4):352–360.
90. Park MY, Kim CH, Sohn HJ, et al. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity. Vaccine. 2007;25(42):7322–7330.
91. Tamai H, Watanabe S, Zheng R, et al. Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin Immunol. 2008;127(1):66–77.
92. Song S, Zhang K, You H, et al. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. Clin Exp Immunol. 2010;162(1):75–83.
93. Poschke I, Lovgren T, Adamson L, et al. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother:CII. 2014;63(10):1061–1071.
94. Baker GJ, Yadav VN, Motsch S, et al. Mechanisms of glioma formation:iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia. 2014;16(7):543–561.
95. Khasraw M, Ameratunga MS, Grant R, et al. Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 2014;9:CD008218.
96. Zhang B, Bowerman NA, Salama JK, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007;204(1):49–55.
97. Li B, Lalani AS, Harding TC, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res. 2006;12(22):6808–6816.
98. Bloch O, Crane CA, Fuks Y, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma:a phase II, single-arm trial. Neuro Oncol. 2014;16(2):274–279.
99. Sengupta S, Marrinan J, Frishman C, et al. Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol. 2012;2012:831090.
100. Sanchez-Perez L, Suryadevara CM, Choi BD, et al. Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. Oncoimmunology. 2014;3(7):e944054.
101. Sanchez-Perez LA, Choi BD, Archer GE, et al. Myeloablative temozolomide enhances CD8(+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One. 2013;8(3):e59082.
102. Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011;13(3):324–333.
103. Lamb LS, Bowersock J, Dasgupta A, et al. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge:a strategy for combining chemo- and immunotherapy. PLoS One. 2013;8(1):e51805.
104. Adair JE, Beard BC, Trobridge GD, et al. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med. 2012;4(133):133ra57–33ra57.
105. Adair JE, Johnston SK, Mrugala MM, et al. Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J Clin Invest. 2014;124(9):4082–4092.
106. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses:a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–662.
107. Brown MC, Gromeier M. Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus. Discov Med. 2015;19(106):359–365.
108. Brown MC, Dobrikova EY, Dobrikov MI, et al. Oncolytic polio virotherapy of cancer. Cancer. 2014;120(21):3277–3286.
109. Patel AP. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (New York, NY). 2014;344(6190):1396–1401.
110. Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;17(8):1064–1075.• Reports that PD-L1 expression and sparse to moderate density of TILs are found in a majority of GBM samples.
111. Ohgaki HH. The definition of primary and secondary glioblastoma. Clinical Cancer Research. 2013;19(4):764–772.
112. Crespo J, Sun H, Welling TH, et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013;25(2):214–221.